These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16026300)

  • 41. Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting.
    Correll CU; Yu X; Xiang Y; Kane JM; Masand P
    Ann Clin Psychiatry; 2017 May; 29(2):92-107. PubMed ID: 28463343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
    Suzuki H; Gen K; Takahashi Y
    Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of the negative symptoms of schizophrenia: new treatment options.
    Möller HJ
    CNS Drugs; 2003; 17(11):793-823. PubMed ID: 12921492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy.
    Zun LS
    J Emerg Med; 2018 Mar; 54(3):364-374. PubMed ID: 29361326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions.
    Mantovani C; Labate CM; Sponholz A; de Azevedo Marques JM; Guapo VG; de Simone Brito dos Santos ME; Pazin-Filho A; Del-Ben CM
    J Clin Psychopharmacol; 2013 Jun; 33(3):306-12. PubMed ID: 23609398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intramuscular aripiprazole in the acute management of psychomotor agitation.
    De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
    Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.
    Baker RW; Kinon BJ; Maguire GA; Liu H; Hill AL
    J Clin Psychopharmacol; 2003 Aug; 23(4):342-8. PubMed ID: 12920409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of intranasal haloperidol in an acute Psychiatry Unit: a pilot study on schizophrenic patients with mild-modedate agitation.
    Duñó Ambròs R; Oliva Morera JC; Iglesias-Lepine ML; Palao Vidal D; Monreal Ortiz JAMO; Labad Arias J
    Actas Esp Psiquiatr; 2021 Sep; 49(5):205-209. PubMed ID: 34533203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of the Agitated Patient.
    Wolfe C; McCoin N
    Emerg Med Clin North Am; 2024 Feb; 42(1):13-29. PubMed ID: 37977745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of patients presenting with acute psychotic episodes of schizophrenia.
    Thomas P; Alptekin K; Gheorghe M; Mauri M; Olivares JM; Riedel M
    CNS Drugs; 2009; 23(3):193-212. PubMed ID: 19320529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.
    Turczyński J; Bidzan L; Staszewska-Małys E
    Med Sci Monit; 2004 May; 10(5):PI74-80. PubMed ID: 15114282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing the agitated psychotic patient: a reappraisal of the evidence.
    Allen MH
    J Clin Psychiatry; 2000; 61 Suppl 14():11-20. PubMed ID: 11154012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change.
    Pacciardi B; Calcedo A; Messer T
    Drugs R D; 2019 Mar; 19(1):15-25. PubMed ID: 30721526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New treatments for agitation.
    Citrome L
    Psychiatr Q; 2004; 75(3):197-213. PubMed ID: 15335224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Benzodiazepines, typical and atypical antipsychotics in the management of acute agitation: a review].
    Yildiz A
    Turk Psikiyatri Derg; 2003; 14(2):134-44. PubMed ID: 12844280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.
    Centorrino F; Meyers AL; Ahl J; Cincotta SL; Zun L; Gulliver AH; Kinon BJ; Houston JP
    Hum Psychopharmacol; 2007 Oct; 22(7):455-62. PubMed ID: 17708578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.